ValiRx - Update on proposed sub-license of VAL201
VAL Wed, 23 Mar 2022, 12:56pm GMT
ValiRx accelerates the development of treatments in cancer and women’s health to improve patient lives. We provide the scientific, financial and commercial framework to enable the rapid translation of innovative science into clinical development.
Industry: Health Care
Contact: +44 (0)2476 796496
Dr Suzy Dilly, CEO of ValiRx provides an update on the progress made towards the completion of the proposed sub-license of VAL201 to TheoremRx Inc.